EA201991854A1 - AGONISM ANTIBODIES AGAINST ICOS AND THEIR APPLICATION - Google Patents

AGONISM ANTIBODIES AGAINST ICOS AND THEIR APPLICATION

Info

Publication number
EA201991854A1
EA201991854A1 EA201991854A EA201991854A EA201991854A1 EA 201991854 A1 EA201991854 A1 EA 201991854A1 EA 201991854 A EA201991854 A EA 201991854A EA 201991854 A EA201991854 A EA 201991854A EA 201991854 A1 EA201991854 A1 EA 201991854A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
icos
human
stimulate
methods
Prior art date
Application number
EA201991854A
Other languages
Russian (ru)
Inventor
Джон Дж. Энгельхардт
Марк Дж. Селби
Алан Дж. Корман
Мэри Дайан Фейнгерш
Бренда Л. Стивенс
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Priority claimed from PCT/US2018/026318 external-priority patent/WO2018187613A2/en
Publication of EA201991854A1 publication Critical patent/EA201991854A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к выделенным моноклональным антителам (например, гуманизированным и человеческим моноклональным антителам), которые связываются с человеческим индуцибельным костимулятором Т-клеток (ICOS) и проявляют терапевтически желательные функциональные свойства, например способность стимулировать активность человеческого ICOS. Также обеспечены молекулы нуклеиновых кислот, кодирующие антитела согласно изобретению, векторы экспрессии, клетки-хозяева и способы экспрессии антител согласно изобретению. Также обеспечены иммуноконъюгаты, биспецифические молекулы и фармацевтические композиции, содержащие антитела согласно изобретению. Антитела согласно изобретению можно применять, например, в качестве агониста для стимулирования или усиления иммунного ответа у субъекта, например антигенспецифических Т-клеточных ответов против опухоли или вирусного антигена. Антитела согласно изобретению можно также применять в комбинации с другими антителами (например, антителами к PD-1, PD-L1 и/или CTLA-4) для лечения, например, рака. Таким образом, антитела можно применять в терапевтических применениях и способах для детекции белка ICOS.The present invention relates to isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to the human inducible T-cell co-stimulator (ICOS) and exhibit therapeutically desirable functional properties, for example, the ability to stimulate the activity of human ICOS. Also provided are nucleic acid molecules encoding antibodies according to the invention, expression vectors, host cells and methods for expressing antibodies according to the invention. Immunoconjugates, bispecific molecules and pharmaceutical compositions containing antibodies of the invention are also provided. Antibodies according to the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, for example, antigen-specific T-cell responses against a tumor or a viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., antibodies to PD-1, PD-L1 and / or CTLA-4) for the treatment of, for example, cancer. Thus, antibodies can be used in therapeutic applications and methods for detecting ICOS protein.

EA201991854A 2017-11-03 2018-04-05 AGONISM ANTIBODIES AGAINST ICOS AND THEIR APPLICATION EA201991854A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581412P 2017-11-03 2017-11-03
PCT/US2018/026318 WO2018187613A2 (en) 2017-04-07 2018-04-05 Anti-icos agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA201991854A1 true EA201991854A1 (en) 2020-02-25

Family

ID=69636677

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991854A EA201991854A1 (en) 2017-11-03 2018-04-05 AGONISM ANTIBODIES AGAINST ICOS AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA201991854A1 (en)

Similar Documents

Publication Publication Date Title
NZ754730A (en) Anti-icos agonist antibodies and uses thereof
CY1124944T1 (en) OPTIMIZED ANTI-CD3 AMPHIBID ANTIBODIES AND USES THEREOF
EA201891435A1 (en) HUMANIZED MONOCLONAL ANTIBODIES, MONOCLONAL ANTIBODIES MOUSE OR CHEMERIC MONOCLONAL ANTIBODIES AGAINST CD47
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
JOP20160154B1 (en) Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
EA201791666A1 (en) CD3 ANTIBODIES, CD123 ANTIBODIES AND BISPECIFIC ANTIBODIES THAT SPECIFICALLY CONNECT WITH CD3 AND / OR CD123
BR112018007046A2 (en) isolated antibody or antigen binding fragment, pharmaceutical composition, isolated polynucleotide molecule, vector, cell, and methods for inhibiting the growth of a tumor or tumor cell and for treating a disease or disorder.
MX2021005708A (en) Anti-nkg2a antibodies and uses thereof.
MX2021012074A (en) Antibodies to tigit.
MX2021009852A (en) Human antibodies to pd-1.
EA201891178A1 (en) Bispecific molecules possessing immunoreactivity with respect to PD-1 and CTLA-4, and methods of their use
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
EA201792484A1 (en) NEW CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE OF MYELOMA AND OTHER CANCER IN IMMUNOTHERAPY
EA201890560A1 (en) NEW PEPTIDES, PEPTIDE COMBINATIONS AND FRAMEWORK FOR APPLICATION IN THE IMMUNOTHERAPEUTIC METHOD OF TREATING DIFFERENT CANCER TYPES
EA201890443A1 (en) BISPECIFIC MONOVALENT DIATELS, ABLE TO CONNECT B7-H3 AND CD3 AND THEIR APPLICATION
MY189159A (en) Multispecific antigen-binding molecules and uses thereof
CL2018003608A1 (en) Isolated antibody or antigen binding fragment thereof that specifically binds interleukin-25 hjumana (il-2525); pharmaceutical composition comprising it; use of said pharmaceutical composition to treat a disease or disorder associated with the activity or expression of il-25. (divisional application 201700703)
EA202091569A1 (en) MONOCLONAL ANTIBODIES AND METHODS OF THEIR APPLICATION
EA201991854A1 (en) AGONISM ANTIBODIES AGAINST ICOS AND THEIR APPLICATION
MX2021003756A (en) Pharmaceutical compositions comprising bispecific anti-cd37 antibodies.
AR113220A1 (en) ANTI-ICOS AGONIST ANTIBODIES AND THEIR USES
EA202190818A1 (en) COMBINED THERAPY FOR CANCER
EA201990488A1 (en) NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION
EA202090449A1 (en) BINDING AGENTS, BINDING PD-L1 AND CD137 AND THEIR APPLICATION
EA202192004A1 (en) HUMANIZED MONOCLONAL ANTIBODIES, MOUSE MONOCLONAL ANTIBODIES OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIES